BioCentury | Jul 14, 2017
Strategy

Back to Ipsen’s roots

After spending the last six years plugging revenue holes via licensing and M&A, Ipsen Group is once again on track to meet the 2020 financial targets it set at the beginning of the decade. But...
BC Week In Review | Jun 22, 2017
Clinical News

FDA approves Ipsen's Dysport for adult lower limb spasticity

FDA approved an sBLA to expand the label for Dysport abobotulinumtoxinA (Azzalure - EU) from Ipsen Group (Euronext:IPN; Pink:IPSEY) to treat lower limb spasticity in adults. The product is approved in the U.S. to treat lower...
BC Week In Review | Aug 8, 2016
Clinical News

Dysport abobotulinumtoxinA regulatory update

FDA approved a label expansion for Dysport from Ipsen to include treatment of pediatric lower limb spasticity in children ages >=2. Dysport is already approved in the U.S. in adults to treat cervical dystonia, upper...
BC Week In Review | Apr 4, 2016
Clinical News

Dysport abobotulinumtoxinA: Additional Phase III data

Additional data from a double-blind, international Phase III trial in 241 children ages 2-17 with dynamic equinus foot deformity due to cerebral palsy showed that the 15 U/kg/leg dose of Dysport significantly improved response rate,...
BC Week In Review | Jan 25, 2016
Company News

Ipsen, Nestle deal

Ipsen and Nestle’s Galderma unit again amended a 2007 deal. Ipsen now granted Galderma exclusive rights to develop and commercialize Dysport abobotulinumtoxinA for aesthetic use in China, India, South Korea and Indonesia under undisclosed conditions....
BC Week In Review | Nov 2, 2015
Clinical News

AbobotulinumtoxinA: Additional Phase III data

Additional data from a double-blind, international Phase III trial in 241 children ages 2-17 with lower limb spasticity due to cerebral palsy showed that 10 and 15 U/kg/leg doses of Dysport each met the secondary...
BC Week In Review | Jul 27, 2015
Clinical News

AbobotulinumtoxinA regulatory update

FDA approved an sBLA from Ipsen for Dysport to treat upper limb spasticity in adults to decrease the severity of increased muscle tone in elbow flexors, wrist flexors and finger flexors. The injectable formulation of...
BC Week In Review | Feb 9, 2015
Clinical News

Dysport abobotulinumtoxinA: Phase III data

Top-line data from a double-blind, international Phase III trial in 235 children with hemiparetic or diplegic cerebral palsy with lower limb spasticity showed that 10 and 15 U/kg/leg doses of Dysport each met the primary...
BC Week In Review | Feb 9, 2015
Clinical News

Dysport abobotulinumtoxinA: Phase III data

Top-line data from a double-blind, international Phase III trial in 388 adult hemiparetic patients with lower limb spasticity who experienced a stroke or traumatic brain injury (TBI) showed that 1,500 U Dysport met the primary...
BC Week In Review | Dec 22, 2014
Clinical News

Dysport abobotulinumtoxinA regulatory update

FDA accepted for review an sBLA from Ipsen for Dysport abobotulinumtoxinA to treat upper limb spasticity in adult patients. The injectable formulation of botulinum neurotoxin type A complex supplied as a lyophilized powder is approved...
Items per page:
1 - 10 of 73